Ainos (AIMD) 10-Q 14 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 14, 2018
Document Information [Line Items]
Entity Registrant Name	AMARILLO BIOSCIENCES INC
Entity Central Index Key	1,014,763
Trading Symbol	amar
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		37,417,524
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Assets
Cash and cash equivalents	$ 1,143,317	$ 1,980,015
Inventory		22,666
Receivables	6,727
Advance to related party		58,135
Prepaid expense and other current assets	46,174	23,635
Total current assets	1,196,218	2,084,451
Goodwill	133,449
Patents, net	168,417	182,386
Property and equipment, net	18,997	26,997
Total assets	1,517,081	2,293,834
Liabilities and Stockholders' Deficit
Accounts payable and accrued expenses	137,761	159,300
Advances from investors	56,225	777,258
Convertible notes payable – related party	513,356	886,481
Total current liabilities	707,342	1,823,039
Total liabilities	707,342	1,823,039
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.01 par value: Authorized shares - 10,000,000, Issued and outstanding shares – 0 at September 30, 2018 and December 31, 2017
Common stock, $0.01 par value: Authorized shares - 100,000,000,Issued and outstanding shares – 37,299,276 and 23,156,563 at September 30, 2018 and December 31, 2017, respectively	372,993	231,565
Additional paid-in capital	3,139,033	2,123,205
Accumulated deficit	(2,702,287)	(1,883,975)
Total stockholders’ equity	809,739	470,795
Total liabilities and stockholders’ equity	$ 1,517,081	$ 2,293,834

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	37,299,276	23,156,563
Common stock, shares outstanding (in shares)	37,299,276	23,156,563

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues	$ 14,908		$ 71,748	$ 250,502
Cost of revenues	16,791		60,837	58,801
Gross margin	(1,883)		10,911	191,701
Operating expenses:
Selling, general and administrative expenses	306,965	230,875	859,956	592,822
Total operating expenses	306,965	230,875	859,956	592,822
Operating income (loss)	(308,848)	(230,875)	(849,045)	(401,121)
Other income (expense)
Interest expense	(1,191)	(1,929)	(3,544)	(7,630)
Net income (loss)	(310,039)	(232,804)	(852,589)	(408,751)
Less: Net loss attributable to non-controlling interests			(18,321)
Net income (loss) attributable to common shareholders	$ (310,039)	$ (232,804)	$ (834,268)	$ (408,751)
Basic and diluted net loss per average share available to common shareholders (in dollars per share)	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.02)
Weighted average common shares outstanding – basic and diluted (in shares)	35,199,804	22,789,370	34,715,330	22,500,663

Condensed Consolidated Statemen

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Net cash used in operating activities:	$ (697,341)	$ (188,526)
Cash flows from investing activities
Acquisition of AEI	63,414
Transportation equipment	(4,913)
Investment in patents	(2,858)	(39,945)
Net cash provided by (used in) investing activities	55,643	(39,945)
Cash flows from financing activities
Payments on convertible notes	(195,000)
Proceeds from convertible note payable – related party		95,000
Proceeds from private placement offering		144,375
Net cash provided by financing activities	(195,000)	239,375
Net change in cash	(836,698)	10,904
Cash and cash equivalents at beginning of period	1,980,015	134,125
Cash and cash equivalents at end of period	1,143,317	145,029
Supplemental Cash Flow Information
Cash paid for interest
Cash paid for income taxes
Non-Cash Transactions
Common stock issued for services		10,671
Common stock issued for accrued liabilities	77,250
Common stock issued for advances from investors	721,033
Common stock issued for previously received funds	85,791
Conversion of debt to common stock	178,125
Common stock issued for acquisition of ACTS	152,302
Reversal of previously accrued dividend	$ 34,277

Note 1 - Organization and Busin

Note 1 - Organization and Business	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Business. Amarillo Biosciences, Inc. (the "Company” or “ABI”), is a diversified healthcare company engaged in the discovery and development of pharmaceutical and biotech products. ABI primarily operates through three 1 2

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of presentation. The accompanying financial statements, which should be read in conjunction with the audited financial statements and footnotes included in the Company's Form 10 December 31, 2017, April 17, 2018, not nine three September 30, 2018 not may December 31, 2018.

Note 3 - Principles of Consolid

Note 3 - Principles of Consolidation	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Consolidation [Text Block]	3. Principles of Consolidation . From January 1, 2018 June 30, 2018, 810, 810” July 1, 2018, July 1, 2018. The Company applies the provisions of ASC 810 In general, a VIE is a corporation, partnership, limited-liability corporation, trust, or any other legal structure used to conduct activities or hold assets that either ( 1 2 3 not 4 not ASC 810

Note 4 - Revenue Recognition

Note 4 - Revenue Recognition	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	4. Revenue Recognition In May 2014, 2014 09, Revenue from Contracts with Customers August 2015, March 2016, April 2016, May 2016, December 2016 2015 14, 2016 08, 2016 10, 2016 12 2016 20, five two On January 1, 2018, 606 no no Results for reporting periods beginning after January 1, 2018 606, not 605, The Company's primary source of revenue is the sale of products within three The Medical division currently provides equipment to metabolism treatment centers in Taiwan and Hong Kong. Additionally, this division provides TissueAid TM The Pharmaceutical Division is currently seeking to leverage the Company’s intellectual property and core technology, low-dose oral interferon, to expand treatment of the aforementioned neoplastic, viral, and fibrotic diseases as well as other potential indications. Revenue recognized during the nine September 30, 2018

Note 5 - Financial Condition

Note 5 - Financial Condition	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Financial Condition [Text Block]	5. Financial Condition. These financial statements have been prepared in accordance with United States generally accepted accounting principles, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not no The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not There can be no may may may

Note 6 - Common Stock

Note 6 - Common Stock	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	6. Common Stock. The shareholders have authorized 100,000,000 September 30, 2018, 45,968,528 37,299,276 2,827,305 two 144,330 300,000 452,617 950,000 3,995,000 On March 10, 2016, 5,000,000 2016 2 $.1875 $937,500 On September 30, 2016, 2016 2 2016 2 10,000,000 $.1875 $1,875,000. one 1 On October 26, 2017, 2016 2 six 6 2016 2 15,000,000 2016 1 $.1875 $2,812,500. During the first 2017, 270,000 $.1875 $50,625. No second 2017. third 2017, 500,000 $.1875 $93,750. 200,000 $.1875 $37,500. During the first 2018, 7,579,059 2016 2 $.1875 September 13, 2017. September 18, 2017 December 26, 2017. first 2018, 1,901,941 2016 3 $.25 April 25, 2018. April 25, 2018, 2016 3 2016 3 30,000,000 $.1875 $7,500,000. not April 25, 2018, $721,033 2,884,132 December 26, 2017. 1,901,941 first 2018. 982,191 2016 3 $.25 August 8, 2018, April 25, 2018, 856,843 $214,211 On January 9, 2018, 76,499 10,199 fourth 2017, $21,250. $.2451 December 20, 2016. December 31, 2017. On February 9, 2018, 1,000,000 $187,500 March 18, 2016, April 7, 2016, $.1875 On Apri1 1, 2018, $178,125 950,000 $.1875 On April 25, 2018 2016 3 30 $7.5 one 1 On July 12, 2018, June 20, 2018, four 539,447 Shareholder/Recipient Issue Date Number of Shares Seu Chi Kuo July 12, 2018 179,852 Po Ya Tseng July 12, 2018 179,852 Yasushi Chikagami July 12, 2018 53,891 Stephen/Virginia Chen Living Trust July 12, 2018 125,852 Total 539,447 Dr. Chen is a related party insomuch as he is the CEO of ACTS and ABI. On August 21, 2018, first second 2018 Shareholder/Recipient Quarter Issue Date Shares Issued Share Price Total Price Stephen/Virginia Chen Living Trust 1 st August 21, 2018 128,866 $ .1940 $ 25,000 Stephen/Virginia Chen Living Trust 2 nd August 21, 2018 91,254 $ .2740 $ 25,000 Bernard Cohen 1 st August 21, 2018 15,464 $ .1940 $ 3,000 Bernard Cohen 2 nd August 21, 2018 10,950 $ .2740 $ 3,000 Total 246,534 $ 56,000

Note 7 - Convertible Notes Paya

Note 7 - Convertible Notes Payable - Related Party	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Convertible Notes Payable – Related Party. As of December 31, 2017, $886,481. five January 8, 2018, $25,000 $25,000, $83. On March 8, 2018, $70,000 $70,000, $425. March 9, 2018, $384,555. $100,000 $100,000, $3,260. On April 1, 2018, $178,125 $284,555 April 2, 2018 April 6, 2018, 550,000 400,000 $.1875 $106,430. September 30, 2018 December 31, 2017 Convertible Note payable – related party $ 144,426 $ 144,426 Convertible Note payable – related party 262,500 262,500 Convertible Note payable – related party 106,430 384,555 Convertible Note payable – related party - 70,000 Convertible Note payable – related party - 25,000 Convertible Notes payable – related party $ 513,356 $ 886,481

Note 8 - Warrants

Note 8 - Warrants	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Warrant Disclosure [Text Block]	8. Warrants . On April 15, 2018, 452,617 $.27 April 14, 2020. $75,967 twenty four $9,496 three September 30, 2018, $18,269 nine September 30, 2018. 1 207%; 2 2 3 2.39%.

Note 9 - ACTS Global

Note 9 - ACTS Global	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Variable Interest Entity Disclosure [Text Block]	9. ACTS Global . On May 23, 2016, may may one 1% Since the inception of the Agency Agreement in 2016, no January 1, 2018 $133,000 On June 18, 2018, July 1, 2018, 539,447 July 12, 2018, July 1, 2018.

Note 10 - Related Party

Note 10 - Related Party	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	10. Related Party. On February 9, 2018, 1,000,000 $187,500 March 18, 2016 April 7, 2016, $.1875 On March 27, 2018, January 1, 2018, $240,000 $100,000 $70,000 $12,000 15th 31st first June 30, 2018, 86,698 $21,250 fourth 2017 September 30, 2018, 246,534 $56,000 first second 2018. On April 1, 2018, $178,125 $284,555 On July 12, 2018, 125,852

Note 11 - 2018 Stock Option and

Note 11 - 2018 Stock Option and Award Incentive Plans	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	11. 2018 . On September 26, 2018, Amarillo Biosciences, Inc., 2018 one may six million 6,000,000 The option price per share of Common Stock deliverable upon the exercise of an Incentive Stock Option is 100% $.38 ten 10 20% five 5 one 1 ten 10% 424 110% $.418; five 5 ten 10 five 5 four 4 On September 26, 2018, Amarillo Biosciences, Inc., 2018 may twenty million 20,000,000 $.38 ten 10 five 5 20% one 1 no ten 10% When options are exercised whether they are qualified or nonqualified, the ABI Common Stock shares will be issued pursuant to Rule 144A six A summary of option activity for the years ended September 30, 2018 December 31, 2017 Date Number of Options Qualified Number of Options Nonqualified Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Balance December 31, 2017 - - - - Granted 950,000 3,995,000 $ .384 - Exercised - - - - Expired - - - - Balance September 30, 2018* *950,000 3,995,000 $ .384 5 - Exercisable, September 30, 2018 - - - - - *There is one 10% 500,000 $.418 5 4 25% The Company used the Black-Scholes option pricing model to value the option awards with the following assumptions applied: ( 1 276%; 2 5 3 2.96%. As of September 30, 2018, $1,865,312 5

Note 12 - Subsequent Events

Note 12 - Subsequent Events	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	12. Subsequent Events . The following stock was issued on October 12, 2018, 3 rd 1 73,529 $.34 $25,000 2 8,824 $.34 $3,000 3 i2 18,248 $.2740 $5,000 April 15 – 30, May, June, 2018, ( 2.5 $2,000 4 i2 17,647 $.34 $6,000 July, August, September, 2018 ( 3 $2,000 During October November 2018, 1,550,000 $387,500 2016 3 not November 14, 2018.

Note 6 - Common Stock (Tables)

Note 6 - Common Stock (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Issuance of Common Stock for Acquisition [Table Text Block]	Shareholder/Recipient Issue Date Number of Shares Seu Chi Kuo July 12, 2018 179,852 Po Ya Tseng July 12, 2018 179,852 Yasushi Chikagami July 12, 2018 53,891 Stephen/Virginia Chen Living Trust July 12, 2018 125,852 Total 539,447
Schedule of Stock Compensation [Table Text Block]	Shareholder/Recipient Quarter Issue Date Shares Issued Share Price Total Price Stephen/Virginia Chen Living Trust 1 st August 21, 2018 128,866 $ .1940 $ 25,000 Stephen/Virginia Chen Living Trust 2 nd August 21, 2018 91,254 $ .2740 $ 25,000 Bernard Cohen 1 st August 21, 2018 15,464 $ .1940 $ 3,000 Bernard Cohen 2 nd August 21, 2018 10,950 $ .2740 $ 3,000 Total 246,534 $ 56,000

Note 7 - Convertible Notes Pa_2

Note 7 - Convertible Notes Payable - Related Party (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	September 30, 2018 December 31, 2017 Convertible Note payable – related party $ 144,426 $ 144,426 Convertible Note payable – related party 262,500 262,500 Convertible Note payable – related party 106,430 384,555 Convertible Note payable – related party - 70,000 Convertible Note payable – related party - 25,000 Convertible Notes payable – related party $ 513,356 $ 886,481

Note 11 - 2018 Stock Option a_2

Note 11 - 2018 Stock Option and Award Incentive Plans (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Date Number of Options Qualified Number of Options Nonqualified Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Balance December 31, 2017 - - - - Granted 950,000 3,995,000 $ .384 - Exercised - - - - Expired - - - - Balance September 30, 2018* *950,000 3,995,000 $ .384 5 - Exercisable, September 30, 2018 - - - - -

Note 4 - Revenue Recognition (D

Note 4 - Revenue Recognition (Details Textual)	9 Months Ended
	Sep. 30, 2018
Number of Operating Segments	3

Note 6 - Common Stock (Details

Note 6 - Common Stock (Details Textual) - USD ($)	Aug. 08, 2018	Jul. 12, 2018	Apr. 25, 2018	Apr. 06, 2018	Apr. 02, 2018	Apr. 01, 2018	Feb. 09, 2018	Jan. 09, 2018	Oct. 26, 2017	Sep. 30, 2016	Mar. 10, 2016	Mar. 31, 2018	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Dec. 31, 2017	Dec. 26, 2017
Common Stock, Shares Authorized																100,000,000			100,000,000
Common Stock, Shares Outstanding and Reserved																45,968,528
Common Stock, Shares, Issued, Total																37,299,276			23,156,563
Common Stock, Shares Subscribed but Unissued																2,827,305
Shares Authorized During Period, Private Placement									15,000,000	10,000,000	5,000,000
Amount of Private Placement									$ 2,812,500	$ 1,875,000	$ 937,500
Proceeds from Issuance of Private Placement													$ 93,750		$ 50,625		$ 144,375
Debt Conversion, Original Debt, Amount																$ 178,125
Stock Issued During Period, Shares, Acquisitions		539,447
ACTS Global Healthcare, Inc. [Member]
Stock Issued During Period, Shares, Acquisitions		539,447
Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues							1,000,000
Shares Issued, Price Per Share				$ 0.1875	$ 0.1875	$ 0.1875	$ 0.1875					$ 0.194						$ 0.274
Common Stock, Value, Subscriptions							$ 187,500
Debt Conversion, Original Debt, Amount						$ 178,125
Debt Conversion, Converted Instrument, Shares Issued				400,000	550,000	950,000
Qualified Options [Member]
Common Stock, Capital Shares Reserved for Future Issuance																950,000
Nonqualified Options [Member]
Common Stock, Capital Shares Reserved for Future Issuance																3,995,000
Warrant [Member]
Common Stock, Capital Shares Reserved for Future Issuance																452,617
Private Placement [Member]
Common Stock, Capital Shares Reserved for Future Issuance																300,000
Shares Authorized During Period, Private Placement			30,000,000
Sale of Stock, Price Per Share			$ 0.1875						$ 0.1875	$ 0.1875	$ 0.1875
Amount of Private Placement			$ 7,500,000
Stock Issued During Period, Shares, New Issues													500,000	0	270,000
Shares Issued, Price Per Share													$ 0.1875		$ 0.1875		$ 0.1875
Private Placement 2016-2 [Member]
Stock Issued During Period, Shares, New Issues												7,579,059
Shares Issued, Price Per Share												$ 0.1875
Private Placement 2016-3 [Member]
Stock Issued During Period, Shares, New Issues	982,191											1,901,941
Shares Issued, Price Per Share	$ 0.25											$ 0.25
Subscription Agreement [Member]
Common Stock, Shares Subscribed but Unissued																				2,884,132
Stock Issued During Period, Shares, New Issues												1,901,941
Common Stock, Value, Subscriptions																				$ 721,033
Stock Issued for Commission [Member]
Stock Issued During Period, Shares, New Issues	856,843
Stock Issued During Period, Value, New Issues	$ 214,211
Officer [Member]
Common Stock, Capital Shares Reserved for Future Issuance																144,330
Chief Executive Officer [Member]
Proceeds from Issuance of Private Placement													$ 37,500
Deferred Compensation Arrangement with Individual, Shares Issued								76,499
Chief Executive Officer [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues													200,000
Shares Issued, Price Per Share													$ 0.1875				$ 0.1875
Chief Financial Officer [Member]
Deferred Compensation Arrangement with Individual, Shares Issued								10,199
CEO and CFO [Member]
Shares Issued, Price Per Share								$ 0.2451
Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued								$ 21,250

Note 6 - Common Stock - Voting

Note 6 - Common Stock - Voting Shares Issued (Details)	Jul. 12, 2018shares
Stock Issued During Period, Shares, Acquisitions	539,447
Seu Chi Kuo [Member]
Stock Issued During Period, Shares, Acquisitions	179,852
Po Ya Tseng [Member]
Stock Issued During Period, Shares, Acquisitions	179,852
Yasushi Chikagami [Member]
Stock Issued During Period, Shares, Acquisitions	53,891
Chief Executive Officer [Member]
Stock Issued During Period, Shares, Acquisitions	125,852

Note 6 - Common Stock - Issuanc

Note 6 - Common Stock - Issuance of Stock Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2018	Sep. 30, 2018	Apr. 06, 2018	Apr. 02, 2018	Apr. 01, 2018	Feb. 09, 2018
Chief Executive Officer [Member]
Shares Issued (in shares)	91,254	128,866
Share Price (in dollars per share)	$ 0.274	$ 0.194	$ 0.274		$ 0.1875	$ 0.1875	$ 0.1875	$ 0.1875
Total Price	$ 25,000	$ 25,000
Chief Financial Officer [Member]
Shares Issued (in shares)	10,950	15,464
Share Price (in dollars per share)	$ 0.274	$ 0.194	$ 0.274
Total Price	$ 3,000	$ 3,000
CEO and CFO [Member]
Shares Issued (in shares)			86,698	246,534
Total Price			$ 21,250	$ 56,000

Note 7 - Convertible Notes Pa_3

Note 7 - Convertible Notes Payable - Related Party (Details Textual) - USD ($)	Apr. 06, 2018	Apr. 02, 2018	Apr. 01, 2018	Mar. 09, 2018	Mar. 08, 2018	Jan. 18, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Feb. 09, 2018	Jan. 08, 2018	Dec. 31, 2017
Notes Payable, Convertible, Related Parties, Classified Current							$ 513,356					$ 886,481
Chief Executive Officer [Member]
Notes Payable, Convertible, Related Parties, Classified Current					$ 384,555		513,356				$ 25,000	886,481
Repayments of Related Party Debt				$ 100,000	70,000	$ 25,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total				$ 3,260	$ 425	$ 83
Debt Conversion, Converted Instrument, Amount			$ 178,125
Debt Conversion, Converted Instrument, Shares Issued	400,000	550,000	950,000
Shares Issued, Price Per Share	$ 0.1875	$ 0.1875	$ 0.1875					$ 0.274	$ 0.194	$ 0.1875
Chief Executive Officer [Member] | Third Issuance [Member]
Notes Payable, Convertible, Related Parties, Classified Current			$ 106,430				$ 106,430		$ 284,555			$ 384,555

Note 7 - Convertible Notes Pa_4

Note 7 - Convertible Notes Payable - Related Party - Related Party Transactions, Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2018	Apr. 01, 2018	Mar. 31, 2018	Mar. 08, 2018	Jan. 08, 2018	Dec. 31, 2017
Convertible Note payable – related party	$ 513,356					$ 886,481
Chief Executive Officer [Member]
Convertible Note payable – related party	513,356			$ 384,555	$ 25,000	886,481
Chief Executive Officer [Member] | First Issuance [Member]
Convertible Note payable – related party	144,426					144,426
Chief Executive Officer [Member] | Second Issuance [Member]
Convertible Note payable – related party	262,500					262,500
Chief Executive Officer [Member] | Third Issuance [Member]
Convertible Note payable – related party	106,430	$ 106,430	$ 284,555			384,555
Chief Executive Officer [Member] | Fourth Issuance [Member]
Convertible Note payable – related party						70,000
Chief Executive Officer [Member] | Fifth Issuance [Member]
Convertible Note payable – related party						$ 25,000

Note 8 - Warrants (Details Text

Note 8 - Warrants (Details Textual) - Warrants Issued to Consultants [Member]	3 Months Ended	9 Months Ended
	Sep. 30, 2018USD ($)yr	Sep. 30, 2018USD ($)yr	Apr. 15, 2018USD ($)$ / sharesshares
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			452,617
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 0.27
Warrants and Rights Outstanding			$ 75,967
Warrants and Rights Outstanding, Term			2 years
Issuance of Stock and Warrants for Services or Claims	$ 9,496	$ 18,269
Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	2.07	2.07
Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr	2	2
Measurement Input, Discount Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0239	0.0239

Note 9 - ACTS Global (Details T

Note 9 - ACTS Global (Details Textual) - USD ($)	Jul. 12, 2018	Sep. 30, 2018	Dec. 31, 2017
Goodwill, Ending Balance		$ 133,449
Stock Issued During Period, Shares, Acquisitions	539,447
ACTS Global Healthcare, Inc. [Member]
Stock Issued During Period, Shares, Acquisitions	539,447
ACTS Global Healthcare, Inc. [Member] | Variable Interest Entity, Primary Beneficiary [Member]
Percentage to be Paid to Affiliate for Services Rendered		1.00%
Goodwill, Ending Balance		$ 133,000

Note 10 - Related Party (Detail

Note 10 - Related Party (Details Textual) - USD ($)	Jul. 12, 2018	Apr. 01, 2018	Feb. 09, 2018	Jan. 01, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Apr. 06, 2018	Apr. 02, 2018	Mar. 08, 2018	Jan. 08, 2018	Dec. 31, 2017
Debt Conversion, Original Debt, Amount								$ 178,125
Notes Payable, Convertible, Related Parties, Classified Current								513,356						$ 886,481
Stock Issued During Period, Shares, Acquisitions	539,447
Chief Executive Officer [Member]
Stock Issued During Period, Shares, Acquisitions	125,852
Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues			1,000,000
Common Stock, Value, Subscriptions			$ 187,500
Shares Issued, Price Per Share		$ 0.1875	$ 0.1875		$ 0.274	$ 0.194	$ 0.274			$ 0.1875	$ 0.1875
Officer Compensation, Annual Compensation, Cash				$ 240,000
Officer Compensation, Annual Compensation, Share Value				100,000
Stock Issued During Period, Shares, Share-based Compensation, Gross					91,254	128,866
Stock Issued During Period, Value, Share-based Compensation, Gross					$ 25,000	$ 25,000
Debt Conversion, Original Debt, Amount		$ 178,125
Notes Payable, Convertible, Related Parties, Classified Current								513,356				$ 384,555	$ 25,000	886,481
Chief Executive Officer [Member] | Third Issuance [Member]
Notes Payable, Convertible, Related Parties, Classified Current		$ 106,430				$ 284,555		$ 106,430						$ 384,555
Chief Financial Officer [Member]
Shares Issued, Price Per Share					$ 0.274	$ 0.194	$ 0.274
Officer Compensation, Annual Compensation, Cash				70,000
Officer Compensation, Annual Compensation, Share Value				$ 12,000
Stock Issued During Period, Shares, Share-based Compensation, Gross					10,950	15,464
Stock Issued During Period, Value, Share-based Compensation, Gross					$ 3,000	$ 3,000
CEO and CFO [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross							86,698	246,534
Stock Issued During Period, Value, Share-based Compensation, Gross							$ 21,250	$ 56,000

Note 11 - 2018 Stock Option a_3

Note 11 - 2018 Stock Option and Award Incentive Plans (Details Textual) - USD ($)	Sep. 26, 2018	Sep. 30, 2018		Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance		$ 0.384
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		276.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Discount Rate		2.96%
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 1,865,312
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		5 years
Qualified Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	6,000,000
Stock Option Price, Percent	100.00%
Stock Option, Exercise Price	$ 0.38
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		950,000	[1]
Qualified Options [Member] | Stock Owner With Over 10 Percent Ownership [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance		$ 0.418
Qualified Options [Member] | If Option Grantee Owns or Controls Over Ten Percent of Outstanding Stock [Member]
Stock Option Price, Percent	110.00%
Stock Option, Exercise Price	$ 0.418
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Qualified Options [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche One [Member] | Stock Owner With Over 10 Percent Ownership [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche Two [Member] | Stock Owner With Over 10 Percent Ownership [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche Three [Member] | Stock Owner With Over 10 Percent Ownership [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche Four [Member] | Stock Owner With Over 10 Percent Ownership [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Qualified Options [Member] | Share-based Compensation Award, Tranche Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Nonqualified Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	20,000,000
Stock Option, Exercise Price	$ 0.38
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		3,995,000
Nonqualified Options [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Nonqualified Options [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Nonqualified Options [Member] | Share-based Compensation Award, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Nonqualified Options [Member] | Share-based Compensation Award, Tranche Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Nonqualified Options [Member] | Share-based Compensation Award, Tranche Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
[1]	There is one stock owner over 10% currently holding 500,000 qualified options. The exercise price for this Option-Holder would be $.418 with an exercise period of 5 years and a vesting period of 4 years at 25% per year.

Note 11 - 2018 Stock Option a_4

Note 11 - 2018 Stock Option and Award Incentive Plans - Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares
Weighted Average Exercise Price, Outstanding (in dollars per share) | $ / shares
Weighted Average Exercise Price, Granted (in dollars per share) | $ / shares	0.384
Weighted Average Exercise Price, Outstanding (in dollars per share) | $ / shares	$ 0.384
Weighted Average Remaining Contractual Term, Outstanding (Year)	5 years
Aggregate Intrinsic Value, Outstanding | $
Weighted Average Exercise Price, Exercisable (in dollars per share) | $ / shares
Weighted Average Remaining Contractual Term, Exercisable (Year)
Aggregate Intrinsic Value, Exercisable | $
Qualified Options [Member]
Number of Options, Outstanding (in shares)
Number of Options, Granted (in shares)	950,000
Number of Options, Outstanding (in shares)	950,000	[1]
Number of Options, Exercisable (in shares)
Nonqualified Options [Member]
Number of Options, Outstanding (in shares)
Number of Options, Granted (in shares)	3,995,000
Number of Options, Outstanding (in shares)	3,995,000
Number of Options, Exercisable (in shares)
[1]	There is one stock owner over 10% currently holding 500,000 qualified options. The exercise price for this Option-Holder would be $.418 with an exercise period of 5 years and a vesting period of 4 years at 25% per year.

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - USD ($)	Oct. 12, 2018	Aug. 08, 2018	Feb. 09, 2018	Nov. 13, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Apr. 06, 2018	Apr. 02, 2018	Apr. 01, 2018
Proceeds from Issuance of Private Placement							$ 93,750	$ 50,625		$ 144,375
Private Placement 2016-3 [Member]
Shares Issued, Price Per Share		$ 0.25				$ 0.25
Stock Issued During Period, Shares, New Issues		982,191				1,901,941
Chief Executive Officer [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross					91,254	128,866
Shares Issued, Price Per Share			$ 0.1875		$ 0.274	$ 0.194					$ 0.1875	$ 0.1875	$ 0.1875
Stock Issued During Period, Value, Share-based Compensation, Gross					$ 25,000	$ 25,000
Stock Issued During Period, Shares, New Issues			1,000,000
Chief Financial Officer [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross					10,950	15,464
Shares Issued, Price Per Share					$ 0.274	$ 0.194
Stock Issued During Period, Value, Share-based Compensation, Gross					$ 3,000	$ 3,000
Subsequent Event [Member] | Private Placement 2016-3 [Member]
Stock Issued During Period, Shares, New Issues				1,550,000
Proceeds from Issuance of Private Placement				$ 387,500
Subsequent Event [Member] | Chief Executive Officer [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross	73,529
Shares Issued, Price Per Share	$ 0.34
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 25,000
Subsequent Event [Member] | Chief Financial Officer [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross	8,824
Shares Issued, Price Per Share	$ 0.34
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 3,000
Subsequent Event [Member] | Executive Advisor for Periods April 15 through 30, May, and June 2018 [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross	18,248
Shares Issued, Price Per Share	$ 0.274
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 5,000
Contractual Obligation, Term	75 days
Contractual Obligation, Payment Per Month	$ 2,000
Subsequent Event [Member] | Executive Advisor for Periods July, August, and September 2018 [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross	17,647
Shares Issued, Price Per Share	$ 0.34
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 6,000
Contractual Obligation, Term	90 days
Contractual Obligation, Payment Per Month	$ 2,000